Eli Lilly fails to get European approval for Alzheimer's drug Kisunla

Lilly will seek review of decision which said drug's benefits don’t outweigh risk of potentially fatal bleeding in the brain

Eli Lilly’s Alzheimer’s disease drug Kisunla failed to get the backing of the European Medicines Agency. Lilly said it will seek another review. Picture: Larry Cummins 

Eli Lilly’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the brain.

Lilly had sought to get the drug cleared for early Alzheimer’s disease. The recommendation on Friday from the European Medicines Agency’s drug advisory committee is pending a final decision by the European Commission. Lilly said it will seek another review, calling the opinion "disappointing”, in a statement.